<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80709">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037347</url>
  </required_header>
  <id_info>
    <org_study_id>0901004673</org_study_id>
    <secondary_id>020901</secondary_id>
    <nct_id>NCT02037347</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis</brief_title>
  <official_title>Palifermin Treatment of Toxic Epidermal Necrolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brett King</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the ability of palifermin (a recombinant human keratinocyte growth factor) to
      decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis
      and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is
      extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal
      tract, respiratory and genitourinary systems.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time-to-cutaneous re-epithelialization</measure>
    <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-mucosal re-epithelialization</measure>
    <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-cessation of epidermal necrosis</measure>
    <time_frame>The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Toxic Epidermal Necrolysis</condition>
  <condition>Stevens-Johnson Syndrome</condition>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <arm_group_label>Palifermin</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in
             more advanced disease necrosis of the entire epidermis

          -  Epidermal detachment or erythematous to purpuric macules involving more than 10% of
             body surface area in addition to involvement of the oropharynx; there may be further
             involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract,
             respiratory and genitourinary epithelia

          -  Age of 18 years old or older

          -  The patient is expected to survive longer than 48 hours

        Exclusion Criteria:

          -  Skin detachment above 90% of the body surface area

          -  Skin detachment has not progressed during the previous 48 hours

          -  A positive serum pregnancy test

          -  Age &lt; 18 years old

          -  Known hematologic or solid organ malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brett A King, MD, PhD</last_name>
    <phone>203-737-4825</phone>
    <email>brett.king@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alisa Savetamal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brett A King, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Brett King</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epidermal Necrolysis, Toxic</mesh_term>
    <mesh_term>Staphylococcal Scalded Skin Syndrome</mesh_term>
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
